Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors

Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by the presence of the BCR-ABL oncogene. Therapeutic regimens with tyrosine kinase inhibitors (TKIs) specifically targeting BCR-ABL have greatly improved overall survival of CML. However, drug intolerance and related toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yi-Hue, Wei, Shih-Hsiang, Jiang, Jie-Hau, Chang, Yueh-Shih, Liu, Mei-Yin, Fu, Shu-Ling, Huang, Chi-Ying F., Lin, Wey-Jinq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623086/
https://www.ncbi.nlm.nih.gov/pubmed/34830455
http://dx.doi.org/10.3390/ijms222212573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623086/
https://www.ncbi.nlm.nih.gov/pubmed/34830455
http://dx.doi.org/10.3390/ijms222212573

Ejemplares similares